Deborah Watkins Bruner on Side Effects From Platinum-Based Drugs in Ovarian Cancer

Article

Deborah Watkins Bruner, PhD, RN, FAAN, from the Nell Hodgson Woodruff School of Nursing at Emory University, discusses side effects associated with platinum-based drugs for the treatment of ovarian cancer.

Deborah Watkins Bruner, PhD, RN, FAAN, professor, Nell Hodgson Woodruff School of Nursing, Emory University, discusses side effects associated with platinum-based drugs for the treatment of ovarian cancer.

Recent Videos
Optimizing RCC Treatment: Integrating Patient-Reported Outcomes and Clinician Insights
Optimizing RCC Treatment: Integrating Patient-Reported Outcomes and Clinician Insights
Quality of Life and Treatment Experience: Patient-Reported Outcomes from TiNivo-2
Quality of Life and Treatment Experience: Patient-Reported Outcomes from TiNivo-2
TiNivo-2 Phase 3 Trial: Survival Data and Practical Approaches to Dose Management in Practice
TiNivo-2 Phase 3 Trial: Survival Data and Practical Approaches to Dose Management in Practice
Optimizing VEGFR-TKI Therapy: Perspectives on Patient Selection and Management Strategies in Clinic
Optimizing VEGFR-TKI Therapy: Perspectives on Patient Selection and Management Strategies in Clinic
Tivozanib Monotherapy Efficacy Profile and Clinical Management Strategies in Advanced RCC
Tivozanib Monotherapy Efficacy Profile and Clinical Management Strategies in Advanced RCC
VEGFR-TKI Tivozanib: Rational Treatment Selection Post-ICI Progression
VEGFR-TKI Tivozanib: Rational Treatment Selection Post-ICI Progression
Sequencing Strategies in RCC: Optimizing Treatment Selection After IO-Based Therapy
Sequencing Strategies in RCC: Optimizing Treatment Selection After IO-Based Therapy
First-Line RCC Treatment in 2025: Navigating the Evolving Therapeutic Landscape
First-Line RCC Treatment in 2025: Navigating the Evolving Therapeutic Landscape
5 experts in this video
Evolving Treatment Strategies in Early HER2+ Breast Cancer
5 experts in this video
Barbara's Story: Navigating HER2+ MBC with Brain Metastases & Tucatinib-Based Treatment in the Second-Line Setting
Related Content
Simple line illustration of the female reproductive system with a tumor on the uterine lining, on a light blue background

Pembrolizumab Shows ORR, Tolerability in Previously Treated Gynecologic Cancer

Kristi Rosa
February 11th 2025
Article

Results from the PEACOCC trial warrant further investigation into treatment with pembrolizumab in patients with previously treated CCGC.

The Vitals

Lauren Mahon Offers Nurse Perspectives on PARP Inhibitors As Ovarian Cancer Maintenance Therapy

Lindsay Fischer
June 15th 2023
Podcast

Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.

yellow background with a white outline indicating ovaries and other gynecological structures

Azenosertib Demonstrates Activity and Tolerability in Ovarian Cancer

Ashling Wahner
February 2nd 2025
Article

Azenosertib (ZN-c3) demonstrated activity as a single agent in heavily pretreated patients with platinum-resistant, cyclin E1-positive ovarian cancer.

Oncology Nursing News

A Look Back at 2022 FDA Approvals in Oncology

Oncology Nursing News
January 2nd 2023
Podcast

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

gynecologic cancer

Lunresertib/Camonsertib Combo Yields Promising Response in Gynecologic Cancers

Chris Ryan
December 26th 2024
Article

Lunresertib plus camonsertib showed promising efficacy in advanced endometrial and platinum-resistant ovarian cancers, with ORRs of 25.9% and 37.5%, respectively.

gynecologic system with cancerous tumor

Sacituzumab Tirumotecan Shows Promise in Pretreated Gynecologic Cancer

Ashley Chan
November 18th 2024
Article

Sacituzumab tirumotecan had antitumor activity in pretreated advanced endometrial and ovarian cancer, data showed.